Rilotumumab (Anti-HGF / SF)

Synonyms: AMG 102

Catalog No.A2469 Purity:99%

Rilotumumab (Anti-HGF / SF) is a monoclonal antibody that inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research. MW: 145.5 KD.

Purity & Quality Control

Batch: A246901 Purity: 99% Protein concentration: 14.86mg/ml Endotoxin Level: ＜1EU/mg

Choose Selective c-Met Inhibitors

Name	Citation	c-Met	Others
Foretinib	93	++++	KDR,Tie-2,VEGFR3/FLT4
PHA-665752	91	++	RON,Flk1
SU11274	63	+
SGX-523	133	+++
BMS-777607	56	+++	Axl,RON,Tyro3
Tivantinib	48	+
JNJ-38877605	52	+++
PF-04217903	22	++
MGCD-265 analog	12	++++	RON,VEGFR2,VEGFR1
BMS-754807	51	++	Insulin Receptor,IGF-1R,TrkB
BMS-794833	1	+++	VEGFR2
AMG-208	0	++
MK-2461	4	++++	c-Met (Y1235D),c-Met (Y1230C),c-Met (N1100)
Golvatinib (E7050)	8	+	VEGFR2
AMG-458	0	++++
Tepotinib	18	+++
NVP-BVU972	1	+
Savolitinib (AZD6094)	16	++	p-Met
S49076	1	++++	Mer,Axl,FGFR3
Merestinib (LY2801653)	9	+++
AMG 337	2	++++
NPS-1034	3	+	Axl

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Rilotumumab (Anti-HGF / SF) is a monoclonal antibody that inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research. MW: 145.5 KD.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	872514-65-3
Molecular Weight	145.5 kDa
Isotype	Human IgG2SA
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100mMPro-Ac,20mMArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.